Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC GIP, rat TFA | 99.8% | 5002.58 | 5 MG
GIP, rat TFA is a bioactive peptide of rat origin, also known as glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide. This 42-amino acid peptide is released by K cells in the duodenum and jejunum in response to food intake. GIP, along with GLP, stimulates insulin secretion from pancreatic beta cells and appears to promote beta cell proliferation and survival. Recent studies suggest a role for GIP in lipid homeostasis and a potential function in the pathogenesis of obesity.
- Bioactive peptide of rat origin
- 42-amino acid peptide
- Released by K cells in duodenum and jejunum
- Stimulates insulin secretion from pancreatic beta cells
- Promotes beta cell proliferation and survival
- Plays a role in lipid homeostasis
Medchemexpress LLC 5A2-SC8 TFA | 1857341-90-2 | 98.6% | C93H173N5O20S5.xC2HF3O2 | 1 MG
5A2-SC8 TFA is an ionizable amino lipid utilized in lipid nanoparticles (LNPs), demonstrating significant potential for drug delivery with low in vivo toxicity. It facilitates the efficient delivery of small RNAs, such as siRNA and miRNA, specifically into tumor cells. This compound's LNPs can uniquely influence the delivery fate of RNA within the liver, thereby improving therapeutic outcomes in various cancer models.
- High delivery potential.
- Low in vivo toxicity.
- Enables efficient delivery of small RNAs (siRNA and miRNA) into tumor cells.
- Can alter therapeutic outcomes in cancer models by influencing RNA delivery in the liver.
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 (free base) | 1 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist that significantly enhances the activation and proliferation of T cells. It inhibits the migration and metastasis and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling. This compound reduces the expression of MCAM and N-cadherin, making it suitable for studies on acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Vasoactive intestinal polypeptide (VIP receptor) antagonist
- Enhances T cell activation and proliferation
- Inhibits migration and metastasis of melanoma cells
- Induces apoptosis in melanoma tumor cells
- Inhibits VIP-VPAC2 signaling
- Reduces MCAM and N-cadherin expression
- Useful for acute myeloid leukemia (AML) research
- Useful for uveal melanoma (UVM) research
Medchemexpress LLC Llvk tfa | 585.66 | 5 MG
LLVK TFA is a selective IκB phosphorylation inhibitor. It reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), making it promising for research of inflammatory bowel disease and rheumatoid arthritis.
- Selective IκB phosphorylation inhibitor
- Reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Promising for research of inflammatory bowel disease
- Promising for research of rheumatoid arthritis
Medchemexpress LLC Myr-FEEERA-OH (TFA) | 990.15 | 25 MG
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. It inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function, and can block the GTP usage of Rac1, Rap1, and Rab7.
- Effectively inhibits the infection of CHO-A24 cells
- Myristoylated peptide
- Inhibits interaction of Gα13 with integrin β3
- Blocks GTP usage of Rac1, Rap1, and Rab7
Medchemexpress LLC Gln-AMS TFA | 99.85% | 588.47 | 50 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. It specifically inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM. This product is intended for research use only.
- Inhibits glutaminyl-tRNA synthetase.
- High purity of 99.85%.
- Available in various quantities.
- Data sheet, COA, SDS, and handling instructions provided.
- Supported by customer reviews and publications.
Medchemexpress LLC Trifluoroacetic acid-13C sodium | 286425-32-9 | 98.0% | 137.00 g/mol | C13CF3NaO2 | 1mg
Trifluoroacetic acid-13C sodium is the 13C labeled isotope of Trifluoroacetic acid-13C (sodium) (HY-W754811)[1]
Medchemexpress LLC EZM0414 TFA | 2411759-92-5 | 95.5% | 514.51 | 1 MG
EZM0414 TFA is the TFA salt form of EZM0414, a potent, selective, and orally active inhibitor of SETD2. It is characterized by an IC50 of 18 nM in the SETD2 biochemical assay and 34 nM in the cellular assay. This compound is suitable for research into relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma.
- Potent, selective, orally active inhibitor of SETD2
- Inhibits proliferation of multiple myeloma and diffuse large B-cell lymphoma cell lines
- Inhibits tumor growth in NOD SCID mouse xenograft models
- Shows robust tumor growth regressions in t(4;14) multiple myeloma cell line-derived xenograft models
- Associated with reductions in intratumoral H3K36me3 levels
- Demonstrates high oral bioavailability in rats and mice
- Well-tolerated in animal studies
Medchemexpress LLC Nampt-IN-10 (TFA) | 2567724-20-1 | >98.6% | 701.59 | 25 MG
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. It shows cellular potency to A2780 and CORL23 cell lines with IC50s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs.
- Shows cellular potency to A2780, CORL23, and c-Kit and HER2 expressing cell lines.
- IC50 values are 5 nM (A2780), 19 nM (CORL23), 2 nM (NCI-H526 with c-Kit expressing), 0.4 nM (MDA-MB453 with HER2 expressing), and 1 nM (NCI-N87 with HER2 expressing).
- Can be used as a novel non-antimitotic payload for ADCs.
Pfaltz & Bauer Trifluoroacetic acid anhydride 100G | 407-25-0
Trifluoroacetic acid anhydride 100G | 407-25-0
Apexbio Technology LLC Protease Inhibitor Cocktail for bacterial cell extracts (100 X in DMSO) 10x(1ml A 1ml B)
Under stable environmental conditions endogenous protein synthesis and degradation are balanced thus maintaining stable cellular protein levels Cell crude extracts contain numerous endogenous enzymes such as phosphatases and proteases that can degrade proteins in the extracts During in vitro protein extraction from cells and tissues protein synthesis practically ceases while protein degradation increases The optimal way to enhance yields of intact proteins is to add inhibitors for these known enzymes The Protease Inhibitor Cocktail for bacterial cell extracts (100X in DMSO) is designed for bacterial extracts to enhance the stability of proteins This cocktail inhibits proteases responsible for degrading non-phosphorylated or phosphorylated protein substrates This Protease Inhibitor Cocktail is provided as a ready-to-use solution and it is formulated in DMSO
Medchemexpress LLC Ceftolozane TFA | 1628046-32-1 | 98.2% | 780.71 | C25H31F3N12O10S2 | 5 MG
Ceftolozane TFA is the trifluoroacetic acid (TFA) salt of a cephalosporin antibiotic supplied as a solid for research use. It is used to study and inhibit Gram-negative bacterial infections and as a synthetic building block for development of new antibiotic derivatives.
- Cephalosporin-class antibiotic active against Gram-negative bacteria.
- Useful as a synthetic intermediate for antibiotic development.
- High purity (98.2%) suitable for analytical and synthetic work.
- White to off-white solid form for easy handling and storage.
- Available in milligram-scale quantities for research applications.
- Store at -20°C sealed; in solvent, store at -80°C up to 6 months or -20°C up to 1 month.
- For research use only; not for human or veterinary use.
Medchemexpress LLC Vasculotide TFA | 1359657-45-6 | 99.7% | 14000 (average) | 25 MG
Vasculotide TFA is an angiopoietin-1 mimetic that functions as a Tie-2 activator, leading to Tie-2 phosphorylation. This compound exhibits anti-inflammatory and anti-permeability effects, making it relevant for various research applications.
- Ameliorates endotoxin-induced endothelial barrier dysfunction
- Promotes angiogenesis in a mouse model of diabetic ulcer
- Protects mice from vascular leakage
- Reduces mortality in murine abdominal sepsis
- Decreases microvascular leakage
- Improves microcirculatory perfusion in a rat model of hemorrhagic shock
Medchemexpress LLC Ribupatide (TFA) | 2940971-65-1 | 98.74% | 4907.48 | 5 MG
Ribupatide (TFA) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. This compound is used in antidiabetic research and is for research use only. It is orally active and can also be administered by injection.
- Dual GIP and GLP-1 receptor agonist
- Orally active
- Can be administered by injection
- Suitable for antidiabetic research